Post-menopausal women experience adverse changes to the musculoskeletal, metabolic and reproductive systems, resulting from the loss of ovarian hormones (inhibin and oestrogen). Whilst the consequence of oestrogen loss is well-defined, the exact consequence of inhibin loss is unknown. This thesis developed a mouse model of inhibin deficiency, and found inhibin loss promotes obesity - analogous to weight gain in postmenopausal women. This indicates inhibin is a preserver of metabolic health, which may be used to alleviate postmenopausal complications. Accordingly, this thesis generated clinical grade inhibin, with enhanced potency (up to 20-fold), for therapeutic assessment. These tools will determine the physiological and therapeutic potential of inhibin, in a menopause setting.